The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Biologic activity of dasatinib administered as neoadjuvant therapy preceding radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC).
Beatrice Knudsen
No relevant relationships to disclose
Noah M. Hahn
Research Funding - Bristol-Myers Squibb
Siamak Daneshmand
Research Funding - Bristol-Myers Squibb
Edwin M. Posadas
Research Funding - Bristol-Myers Squibb
Sambit Muhanty
No relevant relationships to disclose
Seth P. Lerner
Research Funding - Bristol-Myers Squibb
Guru Sonpavde
No relevant relationships to disclose